US Pharm. 2014;39(4):7.
Silver Spring, MD—Expert advisors to the FDA have
recommended that a new screening test for the human papillomavirus (HPV)
could replace the annual Pap smear for many women. They advise that the
FDA should allow the test to be marketed as a first-line screening tool
for cervical cancer, which causes more than 3,000 deaths annually. Only
women with evidence of active HPV infection would then be given a Pap
test, which is examined for evidence of cancerous or precancerous cells.
HPV is very common and causes not only cervical cancer but cancer of
the mouth, throat, penis, and other areas. “If approved, the cobas HPV
Test would become the first and only HPV test indicated as the
first-line primary screen of cervical cancer in the U.S.,” a
representative from Roche, the test’s manufacturer, stated.
To comment on this article, contact email@example.com.